^
    Back
    Association details:
    Biomarker:No biomarker
    Cancer:Marginal Zone Lymphoma
    Regimen:R-CVP (cyclophosphamide + prednisone + Rituxan (rituximab) + vincristine)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: A2 - Guideline
    Source:
    ESMO.org
    Title:

    Marginal zone lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

    Published date:
    01/06/2020
    Excerpt:
    Summary of recommendations: Chemoimmunotherapy is recommended in patients with NMZL (e.g. R-bendamustine, R-CHOP, R-CVP) [IV, B].
    DOI:
    10.1016/j.annonc.2019.10.010
    Evidence Level:
    Sensitive: A2 - Guideline
    New
    Source:
    NCCN
    Excerpt:
    Marginal Zone Lymphoma: Second-Line and subsequent therapy...CVP (cyclophosphamide, vincristine, prednisone) + Rituximab